How to treat negative symptoms of schizophrenia? Case report of the patient Case report
Article Sidebar
Published:
Dec 1, 2024
Keywords:
schizophrenia, negative symptoms, cariprazine
Main Article Content
Abstract
The negative symptoms of schizophrenia are a serious problem related not only to the treatment itself, but also seriously affect the functioning of patients and their families and relatives. Recently, we have more and more new pharmacological treatment options to improve the quality of life of patients. We presented case report of a patient with a variety of symptoms, including negative symptoms with the path of her treatment.
Article Details
How to Cite
Szulc, A. (2024). How to treat negative symptoms of schizophrenia? Case report of the patient. Medycyna Faktow (J EBM), 17(3(64), 427-430. https://doi.org/10.24292/01.MF.0324.17
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. WHO. Klasyfikacja ICD-11.
2. Gałecki P, Szulc A. Psychiatria. Edra Urban, Warszawa 2018.
3. Gałecki P, Szulc A. Psychiatria. Rozpoznania wg ICD-11. Edra Urban, Warszawa 2023.
4. Szulc A, Samochowiec J, Gałecki P et al. Rekomendacje dotyczące leczenia schizofrenii z objawami negatywnymi. Standardy farmakoterapii Polskiego Towarzystwa Psychiatrycznego, część 1. Psychiatr Pol. 2019; 53(3): 497-524.
5. Szulc A, Dudek D, Samochowiec J et. al. Rekomendacje dotyczące leczenia schizofrenii z objawami negatywnymi. Standardy farmakoterapii Polskiego Towarzystwa Psychiatrycznego, część 2. Psychiatr Pol. 2019; 53(3): 525-40.
6. Nemeth G, Laszlovszky I, Czobor P et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017; 389(10074): 1103-13. http://doi.org/10.1016/S0140-6736(17)30060-0.
7. Fagiolini A, Alcala JA, Aubel T et al. Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel. Ann Gen Psychiatry. 2020; 19(55). http://doi.org/10.1186/s12991-020-00305-3.
8. Morozov P, Bekker R and Bykov Y. Cariprazine’s Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective. Front Psychiatry. 2022; 13: 868751. http://doi.org/10.3389/fpsyt.2022.868751.
9. Fleischhacker W, Galderisi S, Laszlovszky I et al. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019; 58: 1-9. http://doi.org/10.1016/j.eurpsy.2019.01.015.
10. Earley W, Guo H, Daniel D et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophr Res. 2019; 204: 282-288. http://doi.org/10.1016/j.schres.2018.08.020.
2. Gałecki P, Szulc A. Psychiatria. Edra Urban, Warszawa 2018.
3. Gałecki P, Szulc A. Psychiatria. Rozpoznania wg ICD-11. Edra Urban, Warszawa 2023.
4. Szulc A, Samochowiec J, Gałecki P et al. Rekomendacje dotyczące leczenia schizofrenii z objawami negatywnymi. Standardy farmakoterapii Polskiego Towarzystwa Psychiatrycznego, część 1. Psychiatr Pol. 2019; 53(3): 497-524.
5. Szulc A, Dudek D, Samochowiec J et. al. Rekomendacje dotyczące leczenia schizofrenii z objawami negatywnymi. Standardy farmakoterapii Polskiego Towarzystwa Psychiatrycznego, część 2. Psychiatr Pol. 2019; 53(3): 525-40.
6. Nemeth G, Laszlovszky I, Czobor P et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017; 389(10074): 1103-13. http://doi.org/10.1016/S0140-6736(17)30060-0.
7. Fagiolini A, Alcala JA, Aubel T et al. Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel. Ann Gen Psychiatry. 2020; 19(55). http://doi.org/10.1186/s12991-020-00305-3.
8. Morozov P, Bekker R and Bykov Y. Cariprazine’s Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective. Front Psychiatry. 2022; 13: 868751. http://doi.org/10.3389/fpsyt.2022.868751.
9. Fleischhacker W, Galderisi S, Laszlovszky I et al. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019; 58: 1-9. http://doi.org/10.1016/j.eurpsy.2019.01.015.
10. Earley W, Guo H, Daniel D et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophr Res. 2019; 204: 282-288. http://doi.org/10.1016/j.schres.2018.08.020.